One of many highlights at SILMO in Paris is the display of finalists in the Optical Design Contest. A true springboard for tomorrow’s talents,
Alcon is expanding into the treatment of dry age-related macular degeneration (AMD), announcing that it will acquire LumiThera and its photobiomodulation (PBM) device for
Enrolment has completed in the PHOENIX trial, a global, 24-month Phase 3 pivotal trial evaluating the safety and tolerability of Tinlarebant (Belite Bio) and
The Australian Health Practitioner Regulation Agency (Ahpra) is calling for a practitioner member from New South Wales to join the Optometry Board of Australia.
DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.
